ATORVASTATIN;
EZETIMIBE;
FENOFIBRATE;
LOMITAPIDE;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR;
TRIACYLGLYCEROL;
ABDOMINAL PAIN;
ARTICLE;
CANADA;
CHOLESTEROL BLOOD LEVEL;
CONSTIPATION;
DIARRHEA;
DRUG DOSE COMPARISON;
DRUG DOSE INCREASE;
DRUG DOSE TITRATION;
DRUG EFFICACY;
DRUG INHIBITION;
DRUG MANUFACTURE;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TOLERABILITY;
DYSLIPIDEMIA;
EUROPE;
EXPERIMENTAL MONKEY;
FAMILIAL HYPERCHOLESTEROLEMIA;
FOLLOW UP;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL REFLUX;
GASTROINTESTINAL SYMPTOM;
HAMSTER;
HUMAN;
HYPERCHOLESTEROLEMIA;
HYPERLIPIDEMIA;
HYPERLIPOPROTEINEMIA TYPE 2;
HYPERTRANSAMINASEMIA;
IC 50;
INDIGESTION;
ISRAEL;
ITALY;
JAPAN;
LICENCE;
LIPID STORAGE;
LIPOPROTEIN BLOOD LEVEL;
LIVER LEVEL;
LOOSE FECES;
LOW DRUG DOSE;
MAXIMUM TOLERATED DOSE;
MONOTHERAPY;
NONHUMAN;
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;
OUTCOME ASSESSMENT;
PATENT;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PRODUCT DEVELOPMENT;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SIDE EFFECT;
SOUTH AFRICA;
TRIACYLGLYCEROL BLOOD LEVEL;
UNITED STATES;
WEIGHT REDUCTION;
ANIMALS;
ANTICHOLESTEREMIC AGENTS;
BENZIMIDAZOLES;
CARRIER PROTEINS;
DRUGS, INVESTIGATIONAL;
HUMANS;
HYPERCHOLESTEROLEMIA;
HYPERLIPOPROTEINEMIA TYPE I;
HYPERLIPOPROTEINEMIA TYPE II;
HYPERTRIGLYCERIDEMIA;
HYPOLIPIDEMIC AGENTS;
University of Pennsylvania School of Medicine. Penn Researchers Demonstrate Ability of New Therapy to Treat Patients With Severely Elevated Cholesterol Levels. www.uphs.upenn.edu
Aegerion Pharmaceuticals Inc. Aegerion Pharmaceuticals Holds Pre-NDA MeetingWith FDA for Investigational Lomitapide and is on Track for NDA Submission. www.aegerion.com
Aegerion Pharmaceuticals Inc. Aegerion Pharmaceuticals Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile. www.aegerion.com
Aegerion Pharmaceuticals Inc Aegerion Pharmaceuticals Inc.
Aegerion Pharmaceuticals Inc.Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile. www.aegerion.com
Aegerion Pharmaceuticals Inc. New England Journal of Medicine Reports Aegerion0s Lead Compound Reduces LDL By 51% in Patients With a Severe Form of Hypercholesterolemia. www.aegerion.com
A Phase III Study of Microsomal Triglyceride Transfer Protein MTP
A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-Lowering Therapy
A Randomized.Double-Blind Placebo-Controlled Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038 lomitapide and Atorvastatin 20mg vs
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 (Formerly BMS201038) [lomitapide] and Atorvastatin 20mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy
A Randomized Double Blind Comparator-Controlled Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs
A Randomized, Double Blind Comparator-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia
69th Annual Scientific Sessions of the American Diabetes Association: Plus poster abstr. 471-P 5 Jun Available from: URL
Bays HE, Davidson M, Schwartz SL, et al. Body weight reductions with low dose AEGR-733, a microsomal triglyceride transfer protein inhibitor: results from three phase 2 trials. 69th Annual Scientific Sessions of the American Diabetes Association: (plus poster) abstr. 471-P, 5 Jun 2009 Available from: URL: http://ww2aievolution.com
Aegerion Pharmaceuticals Inc. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference. www.aegerion.com
A RandomizedDouble-Blind Active Controlled Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 AEGR-733)and Ezetimibe vs.
A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
A Phase II, fixed-sequenced, open- label, research study to assess pharmacokinetic drug interactions of AEGR-733 on lipid-lowering therapies in healthy volunteers
Aegerion Pharmaceuticals Inc.FDA Grants Orphan Drug Designation to Aegerion Pharmaceuticals' Drug Candidate, Lomitapide, for Treatment of Familial Chylomicronemia. www.aegerion.com
Aegerion Pharmaceuticals Inc.Aegerion Pharmaceuticals Announces Issuance of Patent for Treating Diseases Associated With Hyperlipidemia and Hypercholesterolemia Using Lomitapide. www.aegerion.com, 27 Apr 2011
Aegerion Pharmaceuticals Inc.Aegerion Pharmaceuticals Announces Phase III 56-Week Data in HoFH Patients Taking Investigational Lomitapide is Consistent With 26-Week Data. www.aegerion.com, 31 May 2011
A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide AEGR-733 in patients with homozygous familial hypercholesterolemia: Interim results at 6 months
14 Nov 2009 Available from: URL:
Cuchel M, Meagher E, Marais AD, et al. A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide (AEGR-733) in patients with homozygous familial hypercholesterolemia: Interim results at 6 months. AAP Capital Letters: abstr. 1077, 14 Nov 2009 Available from: URL: http:// scientificsessions.americanheart.org/portal/scientificsessions/ss/program
Aegerion Pharmaceuticals Inc. Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile. www.aegerion. com, 17 Nov 2009
Aegerion Pharmaceuticals Inc. Aegerion Study Shows Combination Treatment With AEGR-733 and Zetia(R) Reduces LDL Levels By 35%After Four Weeks of Therapy. www.aegerion.com, 15 Nov 2006
A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors
DOI 10.1021/jm000494a
Robl JA, Sulsky R, Sun C-Q, et al. A novel series of highly potent benzimidazole- based microsomal triglyceride transfer protein inhibitors. Journal of Medicinal Chemistry 2001 Mar 15; 44: 851-6 (Pubitemid 32861609)
Impact of the MTP-inhibitor AEGR-733 as monotherapy and in combination with ezetimibe on lipid subfractions as measured by NMR spectroscopy
8 Nov Available from: URL:
Samaha FF, McKenney J, Bloedon LT, et al. Impact of the MTP-inhibitor, AEGR-733, as monotherapy and in combination with ezetimibe on lipid subfractions as measured by NMR spectroscopy. 81st Annual Scientific Sessions of the American Heart Association: 469 abstr. 3698, 8 Nov 2008 Available from: URL: http://scientificsessions.americanheart.org
Efficacy and safety of the MTPinhibitor AEGR-733 as monotherapy and in combination with ezetimibe
Oct 31 Suppl No. 18
Samaha FF, McKenney J, Bloedon LT, et al. Efficacy and safety of the MTPinhibitor, AEGR-733, as monotherapy and in combination with ezetimibe. Circulation 2006 Oct 31; 114 (Suppl.): 289, No. 18
